Ena Therapeutics is a biotechnology company aiming to transform the treatment and prevention of respiratory infections.

Ena Therapeutics is developing novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists, that have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterial dissemination to the lungs.

Key potential uses for Ena Therapeutics’s new agents include the prevention of respiratory infection in hospital settings and in at-risk populations in the community including patients with pre-existing lung disease such as asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis as well as infants and young children, the elderly and patients with immune suppression.

Contact information